- Home
- SGLY vs THAR Comparison
SGLY vs THAR Comparison
Compare SGLY & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- THAR
- Stock Information
- Founded
- SGLY 2001
- THAR 2017
- Country
- SGLY United States
- THAR United States
- Employees
- SGLY N/A
- THAR N/A
- Industry
- SGLY
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- THAR Health Care
- Exchange
- SGLY Nasdaq
- THAR Nasdaq
- Market Cap
- SGLY 3.7M
- THAR 3.3M
- IPO Year
- SGLY 2008
- THAR 2022
- Fundamental
- Price
- SGLY $0.92
- THAR $1.51
- Analyst Decision
- SGLY
- THAR Strong Buy
- Analyst Count
- SGLY 0
- THAR 1
- Target Price
- SGLY N/A
- THAR $17.00
- AVG Volume (30 Days)
- SGLY 457.6K
- THAR 26.3K
- Earning Date
- SGLY 05-15-2025
- THAR 05-12-2025
- Dividend Yield
- SGLY N/A
- THAR N/A
- EPS Growth
- SGLY N/A
- THAR N/A
- EPS
- SGLY N/A
- THAR N/A
- Revenue
- SGLY $2,172,036.00
- THAR N/A
- Revenue This Year
- SGLY N/A
- THAR N/A
- Revenue Next Year
- SGLY N/A
- THAR N/A
- P/E Ratio
- SGLY N/A
- THAR N/A
- Revenue Growth
- SGLY N/A
- THAR N/A
- 52 Week Low
- SGLY $0.54
- THAR $0.95
- 52 Week High
- SGLY $7.65
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- SGLY 50.30
- THAR 54.61
- Support Level
- SGLY $0.82
- THAR $1.41
- Resistance Level
- SGLY $1.03
- THAR $1.64
- Average True Range (ATR)
- SGLY 0.14
- THAR 0.11
- MACD
- SGLY -0.01
- THAR 0.01
- Stochastic Oscillator
- SGLY 15.08
- THAR 63.86
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.